※researchmapはコチラから

※IF等の数値は、掲載決定時の情報です。

13.

山元修成・渡辺彰吾．SHRSP5/Dmcrラットの疾患併発性サルコペニアモデルとしての有用性．SHR等疾患モデル共同研究会News Letter (75), 2024年5月. 

12.

Fujii M, Kakimoto M, Sato I, Honma K, Kirihara S, Nakayama H, Fukuoka T, Hirohata S, Kitamori K, Ran S, Yamamoto S, Watanabe S. Uric acid elevation by fructose overload exacerbates NASH and atherosclerosis via oxidative stress. Current Nutrition and Food Science, 2024, 20 (2): 250-261. (IF0.9 , Q4)《LINK》

11. 

Honma K, Kirihara S, Nakayama H, Fukuoka T, Ohara T, Kitamori K, Sato I, Hirohata S, Fujii M, Yamamoto S, Ran S, Watanabe S. Selective autophagy associated with iron overload aggravates non-alcoholic steatohepatitis via ferroptosis. Experimental Biology and Medicine, 2023, 248 (13): 1112-1123. (IF 4.088, Q3) 《PubMed》

10.

Yamamoto S, Sato I, Fujii M, Kakimoto M, Honma K, Kirihara S, Nakayama H, Fukuoka T, Tamura S, Ueda M, Hirohata S, Watanabe S. Therapeutic effect of ouabagenin, a novel liver X receptor agonist, on atherosclerosis in nonalcoholic steatohepatitis in SHRSP5/Dmcr rat model. Canadian Journal of Physiology and Pharmacology, 2023, 101 (9): 455-465. (IF 2.245, Q4)《PubMed》

9. 

Yamamoto S, Honma K, Fujii M, Kakimoto M, Kirihara S, Nakayama H, Kitamori K, Sato I, Hirohata S, Watanabe S. SHRSP5/Dmcr rats fed a high-fat and high-cholesteorl diet develop disease-induced sarcopenia as nonalcoholic steatohepatitis progresses. Annals of Anatomy, 2023, 249: 152104. (IF 2.976, Q1)《PubMed》

8. 

Kakimoto M, Fujii M, Sato I, Honma K, Nakayama H, Kirihara S, Fukuoka T, Ran S, Hirohata S, Kitamori K, Yamamoto S, Watanabe S. Antioxidant action of xanthine oxidase inhibitor febuxostat protects the liver and blood vasculature in SHRSP5/Dmcr rats. Journal of Applied Biomedicine, 2023, 21 (2): 80-90. (IF 0.5, Q4)《PubMed》

7.

Yamamoto S, Sato I, Fujii M, Kakimoto M, Honma K, Akiyama N, Sakai M, Fukuhama N, Kumazaki S, Hirohata S, Kitamori K, Yamori Y, Watanabe S. Increased glycine-conjugated and unconjugated bile acid levels associated with aggravation of nonalcoholic steatohepatitis and cardiovascular disease in SHRSP5/Dmcr rat.  Acta Medica Okayama, 2023, 77 (1): 29-36. (IF 0.744, Q4)《PubMed》

6.

Sato I, Yamamoto S, Kakimoto M, Fujii M, Honma K, Kumazaki S, Matsui M, Nakayama H, Kirihara S, Ran S, Usui S, Shinohata R, Kitamori K, Hirohata S, Watanabe S. Suppression of nitric oxide synthase aggravates non-alcoholic steatohepatitis and atherosclerosis in SHRSP5/Dmcr rat via acceleration of abnormal lipid metabolism. Pharmacological Reports, 2022, 74 (4): 669-683. (IF 3.919, Q2)《PubMed》 

5.

Inagaki J, Nakano A, Hatipoglu OF, Ooka Y, Tani Y, Miki A, Ikemura K, Opoku G, Ando R, Kodama S, Ohtsuki T, Yamaji H, Yamamoto S, Katsuyama E, Watanabe S, Hirohata S. Potential of a novel chemical compound targeting matrix metalloprotease-13 for early osteoarthritis: An in vitro study. International Journal of Molecular Sciences, 2022, 23 (5): 2681. (IF 6.208, Q1)《PubMed》

4.

Sato I, Yamamoto S, Kakimoto M, Fujii M, Honma K, Kumazaki S, Matsui M, Nakayama H, Kirihara S, Ran S, Hirohata S, Watanabe S.Basic characteristics between mechanomyogram and muscle force during twitch and tetanic contractions in rat skeletal muscles. Journal of Electromyography and Kinesiology, 2022, 62: 102627. (IF 2.641, Q4)《PubMed》

3. 

Yamamoto S, Sato I, Fukuhama N, Akiyama N, Sakai M, Kumazaki S, Ran S, Hirohata S, Kitamori K, Yamori Y, Watanabe S. Bile acids aggravate nonalcoholic steatohepatitis and cardiovascular disease in SHRSP5/Dmcr rat model. Experimental and Molecular Pathology, 2020, 114: 104437. (IF 2.28, Q2)《PubMed》

2.

Kumazaki S, Nakamura M, Sasaki S, Tagashira R, Maruyama N, Sato I, Yamamoto S, Ran S, Usui S, Shinohata R, Ohtsuki T, Hirohata S, Kitamori K, Mori M, Yamori Y, Watanabe S. Bile acid metabolism is an intermediary factor between non-alcoholic steatohepatitis and ischemic heart disease in SHRSP5/Dmcr rats. Journal of Nutrition and Food Sciences, 2019, 9(4): 763. 《LINK》

1.

Watanabe S, Kumazaki S, Yamamoto S, Sato I, Kitamori K, Mori M, Yamori Y, Hirohata S. Non-alcoholic steatohepatitis aggravates nitric oxide synthase inhibition-induced arteriosclerosis in SHRSP5/Dmcr rat model. International Journal of Experimental Pathology, 2018, 99(6): 282-294. (IF 1.938, Q3)《PubMed》